BNIP3L and diabetes mellitus: This study offers novel insights into the luteolin’s therapeutic potential in DR, particularly activating mitophagy through the SQSTM1/BNIP3L axis, which expands the scope of natural compounds in addressing this sight-threatening complication of diabetes.